Royal Bank of Canada Buys 12,215 Shares of Invesco Biotechnology & Genome ETF $PBE

Royal Bank of Canada boosted its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 25.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 59,329 shares of the company’s stock after purchasing an additional 12,215 shares during the quarter. Royal Bank of Canada’s holdings in Invesco Biotechnology & Genome ETF were worth $4,698,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PBE. Colonial Trust Advisors acquired a new position in Invesco Biotechnology & Genome ETF in the fourth quarter valued at about $25,000. Fifth Third Bancorp acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the first quarter worth approximately $30,000. Comerica Bank raised its stake in shares of Invesco Biotechnology & Genome ETF by 86.2% in the fourth quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after acquiring an additional 175 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Invesco Biotechnology & Genome ETF by 74.5% in the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after acquiring an additional 245 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of Invesco Biotechnology & Genome ETF by 63.2% in the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after acquiring an additional 342 shares in the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

NYSEARCA PBE opened at $94.22 on Friday. The firm has a market cap of $296.79 million, a PE ratio of 20.44 and a beta of 0.70. Invesco Biotechnology & Genome ETF has a one year low of $66.81 and a one year high of $95.01. The stock’s 50 day simple moving average is $89.26 and its 200 day simple moving average is $83.69.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.